期刊文献+

血清CRP联合CA125、HE4检测对卵巢癌的诊断及病情评估 被引量:7

下载PDF
导出
摘要 目的 探讨血清C反应蛋白(C-reactive protein,CRP)联合CA125、人附睾蛋白4(HE4)检测对卵巢癌的诊断及病情评估的价值.方法 检测98例卵巢癌组和80例健康对照组血清CRP、CA125和HE4水平,并分析卵巢癌组血清CRP、CA125和HE4与临床分期和淋巴结转移的关系,以及联合检测的诊断价值.结果 卵巢癌组血清CRP、CA125和HE4水平均高于对照组(P<0.01).卵巢癌患者FIGO分期Ⅲ/Ⅳ期血清CRP、CA125和HE4水平显著高于Ⅰ/Ⅱ期(P<0.05).淋巴结转移阳性组血清CRP、CA125和HE4水平显著高于淋巴结转移阴性组(P<0.05).3项联合检测时Ⅲ/Ⅳ和淋巴结转移阳性者以2项及2项以上阳性为主,而Ⅰ/Ⅱ期和淋巴结转移阴性者以3项均阴性和单项阳性为主,差异均有统计学意义(P<0.05).结论 血清CRP联合CA125、HE4检测对卵巢癌的诊断及病情评估具有重要的临床价值.
出处 《国际医药卫生导报》 2015年第14期2055-2057,共3页 International Medicine and Health Guidance News
  • 相关文献

参考文献10

二级参考文献43

  • 1黄海燕,朱勇,庄然,许晓光,刘雪松,宋朝君,曹云新,金伯泉.应用红细胞花环形成试验筛选肿瘤膜抗原单克隆抗体[J].第四军医大学学报,2004,25(14):1343-1344. 被引量:33
  • 2吴健民.对肿瘤标志物的再认识[J].中华检验医学杂志,2005,28(1):11-13. 被引量:116
  • 3董兴辉,丁振灿,张秀华.CEA、CA19-9、CA242、CA72-4在大肠癌中的应用价值探讨[J].放射免疫学杂志,2005,18(2):127-128. 被引量:26
  • 4周辉,吴缨,牟洪超,胡雪峰,郭鹭,刘永存,孙茂.C反应蛋白与大肠癌临床病理及预后的关系[J].肿瘤学杂志,2005,11(6):418-419. 被引量:3
  • 5Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics,2002 [J]. CA CancerJ Clin,2005,55(2):74 108.
  • 6Tew WP,Kelsen DP, Ilson DH. Targeted therapies for esopha- geal cancer [J]. Oncologist, 2005,10(8) : 59-60.35 39.
  • 7Dohmoto K, Hojo S, Fujita J, et al. Mechanisms of the release of CYFRA21-1 in human lung cancer cell lines [J]. Lung Cancer, 2000,30(1) ~55-63.
  • 8Sheard MA, Vojtesek B, Simickova M, et al. Release of cytokera- tin-18 and -19 fragments (TPS and CYFRA 21-1) into the extra- cellular space during apoptosis [J]. J Cell Bioehem,2002,85(4) : 670 677.
  • 9Wakatsuki M, Suzuki Y, Nakamoto S, et al. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radia tiontherapy [J]. J Gastroenterol Hepatol, 2007,22(5)~715 719.
  • 10Yi Y, Li B, Wang Z, et al. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of e- sophageal squamous cell carcinoma [J]. Biomarkers, 2009, 14 (7) =480 485.

共引文献33

同被引文献74

  • 1冯蕾 庄敏.宫颈癌新辅助化疗的护理.现代医院,2009,9(1):165-165.
  • 2WIESER A, MAGISTRO G, NOERENBERG DA, et al. First muhiepitope subunit vaccine against extra intestinal pathogenic Escherichia coli delivered by a bacterial type -3 secretion system (33SS) [ J] .Int J Med Microbiol, 2012, 302 ( 1 ) : 10 - 18.
  • 3MOLINA R, JOJ, FILELLA X, et al. C -erbB -2 CEA and CA153 serum levels in the early diagnosis of recurrence in breast cancer patients [ J ]. Anticancer Res, 1999,19:2551 - 2555.
  • 4MORRISON J, HALDAR K, KEHOE S,et al. Chemotherapy ver- sus surgery for initial treatment in advanced ovarian epithelial cancer ~ DB/OL]. Cochrane Database Syst Rev, 2012, 8: CD005343.
  • 5XIE M, ZHANG X, JIA Z,et al. Elastography, a sensitive tool for the evaluation of neoadjuvant chemotherapy in patients with high - grade serous ovarian carcinoma[ J]. Oncol Lett,2014,8 (4) :1652 - 1656.
  • 6MENCZER J, BEN - SHEM E, GOLAN A,et al. The Significance of Normal Pretreatment Levels of CA125 ( < 35 U/mL) in Epithe- lial Ovarian Carcinoma [ J]. Rambam Maimonides Med J, 2015,6 (1) : e0005.
  • 7CHI D S, ZIVANOVIC O, PALAYEKAR M J, et al. A eontempo- rar'y analysis of the ability of preoperative serum CA - 125 to pre- dict primary cytoreductive outcome in patients with advanced ovari- an, tubal and peritoneal carcinoma [ J]. Gynecol Oncol, 2009, 112:6 -10.
  • 8VANOVIC O, SIMA C S, IASONOS A, et al. Exploratory analysis of serum CA - 125 response to surgery and the risk of relapsein pa- tients with FIGO stage IIIC ovarian cancer [ J ]. Gynecol Oncol, 2009,115:209 - 214.
  • 9RIEDINGER J M, WAFFLART J, RICOLLEAU G, et al. CA 125 half - life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome : results of a French multicentric study[ J]. Ann Oncol,2006, 17: 1234 - 1238.
  • 10CRAWFORD S M, PEACE J. Does the nadir CAl25 concentra- tion predict a long - term outcome after chemotherapy for carcino- ma of the ovary? [J]. Ann Oncol, 2005,16:47 -50.

引证文献7

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部